Added to YB: 2026-09-14
Pitch date: 2026-09-10
VSTM [neutral]
Verastem, Inc.
Author Info
No bio for this author
Company Info
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.
Market Cap
$719.1M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.23
P/E
-3.48
EV/Sales
7.62
Sector
Biotechnology
Category
growth
Biotech Conference Coverage Day 3 session 1 - Verastem, Inc.
VSTM (update): Verastem is using its commercial ovarian-cancer business to support development of VS-7375, a selective oral dual ON/OFF KRAS G12D inhibitor. The key October 14 update is expected to add pancreatic, lung and colorectal data; relevant benchmarks are >30% pancreatic response, ~50% lung activity and >30% colorectal response with anti-EGFR therapy. Upside could be considerable, but the stock carries meaningful expectations and three Phase 3 programs would require substantial capital or a partner.
Read full article (1 min)